NCT03922906

Brief Summary

The study aim to evaluate the performance of Pure-Vu System in cleansing patients' colon with history of inadequate bowel preparation who are indicated for a colonoscopy procedure.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2020

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 22, 2019

Completed
9 months until next milestone

Study Start

First participant enrolled

January 21, 2020

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 25, 2020

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 2, 2021

Completed
Last Updated

February 25, 2021

Status Verified

February 1, 2021

Enrollment Period

1 month

First QC Date

April 18, 2019

Last Update Submit

February 23, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Boston Bowel Preparation Scale( BBPS) >1 in All Colon Segments After the Use of Pure-Vu System

    The rating of the cleansing quality was evaluated by using the Boston Bowel Preparation Scale (BBPS), Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side): Score 0- Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared. Score 1- A portion of the mucosa of the colon segment is seen, but other areas of the colon segment are not seen well due to staining, residual stool, and/or opaque liquid. Score 2- A minor amount of residual staining, small fragments of stool, and/or opaque liquid are visible, but the mucosa of the colon segment are seen well. Score 3-The entire mucosa of the colon segment is seen well with no residual staining, small fragments of stool, or opaque liquid. subject consider as having adequate cleaning if BBPS\>1 in all colon segments

    Up to 2 hours

Study Arms (1)

Motus Pure-Vu System

EXPERIMENTAL

The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.

Device: Pure-Vu System

Interventions

Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.

Motus Pure-Vu System

Eligibility Criteria

Age22 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with history of inadequate bowel preparation.
  • Subjects in the age range of 22-75 years inclusive
  • Subjects with BodyMass Index (BMI) within the range of 18.5-35 inclusive
  • Subject has signed the informed consent

You may not qualify if:

  • Patients with active Inflammatory Bowel Disease
  • Patients with previous history of acute diverticulitis disease or with prior incomplete colonoscopy due to diverticular disease
  • Patients with known bowel obstruction / strictures
  • History of prior surgery to colon and/or rectum
  • ASA ≥ III
  • Renal insufficiency (Creatinine ≥ 1.5mg /dL) (based on medical history)
  • Abnormal Liver enzymes (ALT/AST ≥ 2 times upper limits of normal) (based on medical history)
  • Patients taking anticoagulants drugs (excluding aspirin) or dual antiplatelet therapy
  • Patients with known coagulation disorder (INR \>1.5).
  • Patients at risk of hypokalemia or hyponatremia
  • Patients with congestive cardiac failure
  • Pregnancy (as stated by patient) or breast feeding
  • Patients with altered mental status/inability to provide informed consent
  • Patients who have participated in another interventional clinical study in the last 2 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chaim Sheba Medical Center

Tel Litwinsky, 5265601, Israel

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 18, 2019

First Posted

April 22, 2019

Study Start

January 21, 2020

Primary Completion

February 25, 2020

Study Completion

February 2, 2021

Last Updated

February 25, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations